PimedBio’s Cancer Stemness Inhibitor Selected as one of KDDF’s 

"Top 10 Outstanding Projects"

— Recognized for Innovation and Global Commercialization Potential in the 2023 National New Drug Development Project —

PimedBio is proud to announce that its flagship project, "Non-clinical Research and IND Approval of First-in-class Cancer Stemness Inhibitor PMB212," has been selected as one of the Top 10 Outstanding Projects by the Korea Drug Development Fund (KDDF).

This prestigious recognition was awarded during the "2023 National New Drug Development Project Outstanding Project Presentation" held in December 2023. Out of approximately 350 projects supported by the KDDF since 2021, PimedBio was chosen for its exceptional technological breakthroughs and high potential for global success.

• Target: Cancer Stem Cells (CSCs), the root cause of cancer recurrence and metastasis.

• Candidate: PMB212, a first-in-class small molecule inhibitor designed to overcome the limitations of current therapies.

• Evaluation: The project was highly rated for its novel mechanism of action (MoA) and its strategic progression from lead compound discovery to the non-clinical stage.

•  

The KDDF selection committee, composed of internal and external industry experts, evaluated projects based on criteria such as technical excellence, clinical feasibility, and global licensing-out potential. Being named a "Top 10 Project" validates PimedBio’s R&D capabilities and the commercial value of the PMB212 pipeline in the global oncology market.

PimedBio remains dedicated to advancing PMB212 toward clinical trials. This recognition serves as a catalyst for our efforts to secure global partnerships and accelerate the development of life-saving treatments for patients with refractory cancers.

We thank the KDDF for their support and our stakeholders for their continued trust in our vision.